INTRODUCTION: We sought to determine the efficacy of using both irinotecan- and etoposide-containing regimens sequentially for patients with untreated limited-stage small-cell lung cancer. METHODS: Patients with untreated, measurable, limited-stage small-cell lung cancer with performance status 0 to 2, and adequate organ function were eligible. Treatment consisted of induction with cisplatin 30 mg/m and irinotecan 65 mg/m intravenously on day 1 and 8, every 21 days for two cycles. Beginning day 43, daily chest irradiation to 70 Gy was administered concurrently with carboplatin area under curve 5 on day 1, and etoposide 100 mg/m on days 1 to 3, every 21 days for three cycles. The primary objective was to differentiate between 45% and 60% 2-year survival. RESULTS: Two induction cycles were delivered to 72 of 75 eligible patients (96%) and all planned treatment was delivered to 59 patients (79%). Cisplatin and irinotecan induction chemotherapy resulted in complete responses in 7% and partial responses in 64% (response rate 71%, 95% confidence interval [CI], 59%-81%). The best response to all therapy included 88% complete or partial responses (95% CI, 78%-94%). With median follow-up of 57 months, the median progression-free survival and overall survival are 12.6 (95% CI, 9.4-14.7) and 18.1 months (15.8-22.9), respectively. The 1- and 2-year survival was 69% and 31%, respectively. Frequent (>20%) grade 3 and 4 toxicities were neutropenia in 84%, hemoglobin in 36%, platelets in 51%, esophagitis in 22%, and dehydration in 24%. There were no fatal toxicities. CONCLUSIONS: This treatment regimen of irinotecan-cisplatin induction chemotherapy followed by 70 Gy concurrent radiation and etoposide-carboplatin had tolerable toxicity but did not meet the preplanned 2-year survival target for further development.
INTRODUCTION: We sought to determine the efficacy of using both irinotecan- and etoposide-containing regimens sequentially for patients with untreated limited-stage small-cell lung cancer. METHODS:Patients with untreated, measurable, limited-stage small-cell lung cancer with performance status 0 to 2, and adequate organ function were eligible. Treatment consisted of induction with cisplatin 30 mg/m and irinotecan 65 mg/m intravenously on day 1 and 8, every 21 days for two cycles. Beginning day 43, daily chest irradiation to 70 Gy was administered concurrently with carboplatin area under curve 5 on day 1, and etoposide 100 mg/m on days 1 to 3, every 21 days for three cycles. The primary objective was to differentiate between 45% and 60% 2-year survival. RESULTS: Two induction cycles were delivered to 72 of 75 eligible patients (96%) and all planned treatment was delivered to 59 patients (79%). Cisplatin and irinotecan induction chemotherapy resulted in complete responses in 7% and partial responses in 64% (response rate 71%, 95% confidence interval [CI], 59%-81%). The best response to all therapy included 88% complete or partial responses (95% CI, 78%-94%). With median follow-up of 57 months, the median progression-free survival and overall survival are 12.6 (95% CI, 9.4-14.7) and 18.1 months (15.8-22.9), respectively. The 1- and 2-year survival was 69% and 31%, respectively. Frequent (>20%) grade 3 and 4 toxicities were neutropenia in 84%, hemoglobin in 36%, platelets in 51%, esophagitis in 22%, and dehydration in 24%. There were no fatal toxicities. CONCLUSIONS: This treatment regimen of irinotecan-cisplatin induction chemotherapy followed by 70 Gy concurrent radiation and etoposide-carboplatin had tolerable toxicity but did not meet the preplanned 2-year survival target for further development.
Authors: H Ozer; J O Armitage; C L Bennett; J Crawford; G D Demetri; P A Pizzo; C A Schiffer; T J Smith; G Somlo; J C Wade; J L Wade; R J Winn; A J Wozniak; M R Somerfield Journal: J Clin Oncol Date: 2000-10-15 Impact factor: 44.544
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Nasser Hanna; Paul A Bunn; Corey Langer; Lawrence Einhorn; Troy Guthrie; Thaddeus Beck; Rafat Ansari; Peter Ellis; Michael Byrne; Mark Morrison; Subramanian Hariharan; Benjamin Wang; Alan Sandler Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: M Oka; M Fukuda; M Kuba; M Ichiki; T Rikimaru; H Soda; J Tsurutani; Y Nakamura; S Kawabata; K Nakatomi; F Narasaki; S Nagashima; H Takatani; M Fukuda; A Kinoshita; S Kohno Journal: Eur J Cancer Date: 2002-10 Impact factor: 9.162
Authors: Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: Joseph K Salama; Herbert Pang; Jeffrey A Bogart; A William Blackstock; James J Urbanic; Lydia Hogson; Jeffrey Crawford; Everett E Vokes Journal: Lung Cancer Date: 2013-12 Impact factor: 5.705
Authors: Joseph K Salama; Lydia Hodgson; Herbert Pang; James J Urbanic; A William Blackstock; Steven E Schild; Jeffrey Crawford; Jeffrey A Bogart; Everett E Vokes Journal: J Thorac Oncol Date: 2013-08 Impact factor: 15.609
Authors: Thomas E Stinchcombe; Wen Fan; Steven E Schild; Everett E Vokes; Jeff Bogart; Quynh-Thu Le; Charles R Thomas; Martin J Edelman; Leora Horn; Ritsuko Komaki; Harvey J Cohen; Apar Kishor Ganti; Herbert Pang; Xiaofei Wang Journal: Cancer Date: 2018-10-21 Impact factor: 6.860